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Background: In contrast with various pre-clinical studies, recent clinical trials suggest that high dose erythropoietin
(EPO) treatment following kidney transplantation does not improve short-term outcome and that it even increases
the risk of thrombotic events. ARA290 is a non-erythropoietic EPO derivative and does not increase the risk of
cardiovascular events, but potentially has cytoprotective capacities in prevention of renal ischemia/reperfusion
injury.
Methods: Eight female Dutch Landrace pigs were exposed to unilateral renal ischemia for 45 minutes with
simultaneous cannulation of the ureter of the ischemic kidney. ARA290 or saline was administered by an
intravenous injection at 0, 2, 4 and 6 hours post-reperfusion. The animals were sacrificed seven days post-
reperfusion.
Results: ARA290 increased glomerular filtration rate during the observation period of seven days. Furthermore,
ARA290 tended to reduce MCP-1 and IL-6 expression 15 minutes post-reperfusion. Seven days post-reperfusion
ARA290 reduced interstitial fibrosis.
Conclusions: The improvement in renal function following renal ischemia/reperfusion and reduced structural
damage observed in this study by ARA290 warrants further investigation towards clinical application.
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transplantationBackground
Despite many achievements in transplantation the persis-
tent shortage of deceased donors remains a major prob-
lem. This shortage resulted in an evident increase in living
donation, but also forced transplant teams to accept more
kidneys from marginal deceased brain death (DBD) donors
and deceased cardiac death (DCD) donors. In 2011, 50%
of the deceased donor kidneys in the Netherlands were
retrieved from DCD donors while in 1996 this was only
6% [1,2].
A donor kidney is by definition exposed to a period of
ischemia which lasts until the kidney is re-connected to
the circulation of the recipient. This period of ischemia* Correspondence: w.g.van.rijt@umcg.nl
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reproduction in any medium, provided the orcan be divided into three phases: primary warm ischemia,
cold storage and secondary warm ischemia. Primary warm
ischemia is the time between end of cardiovascular circu-
lation and start of cold storage. Cold storage starts when
the donor organ is flushed with 4°C preservation solution.
Secondary warm ischemia is the time between end of cold
storage and reperfusion of the donor organ in the recipient.
The whole ischemic process results in a cascade causing
renal damage and is associated with the phenomenon of is-
chemia/reperfusion (I/R) injury. In DCD donation, the pri-
mary period of warm ischemia is variable and explicitly
extended compared to the controlled circumstances in
DBD donation. This results in a significant increase in
the risk of delayed graft function (DGF) and primary
non function (PNF). Death censored graft survival at 15
years of DCD kidneys is significantly reduced compared
to DBD kidneys, 46% and 60%, respectively. Excluding
primary non-functioning kidneys equals long-term graftLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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function of DCD kidneys appears to be crucial for long-
term survival. The major part of I/R injury manifests it-
self during the reperfusion phase. Therefore, cytoprotec-
tive treatment early on during the reperfusion phase
could key to enhance immediate function and improve
long-term graft survival of DCD kidneys.
Erythropoietin (EPO) is a potential cytoprotective glyco-
protein. In renal I/R models it has been shown that ad-
ministration of EPO before reperfusion [4] as well as after
reperfusion [5] can be cytoprotective. Protective EPO
treatment has pronounced anti-inflammatory and anti-
apoptotic capacities [5,6]. Enhanced activity of endothelial
nitric oxide synthase (eNOS) is presumably responsible
for the immediate effect of EPO on renal function [7,8].
However, the exact pathway of cytoprotection by EPO is
not yet fully elucidated. The proposed cytoprotective
mechanism is binding of EPO to a heteromeric EPOR2-
βcR2 receptor complex consisting of two EPO receptors
and two beta common receptors (EPOR2-βcR2) [9]. The
binding affinity of the classic, erythropoietic complex of
two EPO receptors for EPO is distinctly larger than the
binding affinity of the protective EPOR2-βcR2 complex
[10]. Thus, to induce local tissue protection, consider-
ably higher systemic doses of EPO are required than
the normal therapeutic doses used for stimulation of
erythropoiesis [10].
Renal I/R models have been widely used to mimic
warm ischemic injury following DCD donation. Based
on pre-clinical renal I/R experiments, activation of the
protective EPO pathway could improve quality of DCD
kidney [4-6]. Recently, the protective effect of high dose
EPO treatment in deceased kidney transplantation has
been evaluated in four clinical studies. None of these
studies was able to demonstrate a reduction of DGF or
PNF [11-14]. High dose EPO treatment even resulted in
an increased risk of thrombotic events in the first year
after transplantation (Epoetin 24.4% vs. placebo 6.4%)
[13]. However, the EPO doses were relatively low to in-
duce cytoprotection compared to used doses in most
animal models [4-6]. Therefore it is questionable whether
protective, systemic EPO levels were obtained in these
clinical trials, although the risk of cardiovascular adverse
events was already increased.
To prevent these cardiovascular adverse effects, EPO
derivatives have been developed which only activate the
protective EPOR2-βcR2 complex and do not stimulate
erythropoiesis. ARA290 is the newest generation EPO
analogue. It is a small synthetic peptide, which selec-
tively binds to the EPOR2-βcR2 complex. It has already
been shown that ARA290, also known as pyroglutamate
helix B-surface peptide (pHBSP), is not erythropoietic
[15]. Patel et al showed that administration of ARA290
or EPO after reperfusion improves renal function in arodent model of renal I/R. Mechanistically, ARA290 and
EPO increase the phosphorylation of survival pathway
Akt. Activation of pro-inflammatory glycogen synthase
kinase-3β and nuclear factor-κβ were inhibited by
ARA290 and EPO. Furthermore, ARA290 and EPO were
able to increase phosphorylation of eNOS [16]. The
effect of ARA290 on these pathways could explain both
the anti-inflammatory capacities and the effect on renal
function.
Diminution of I/R injury in rodents showed the potential
of ARA290 as cytoprotective agent following transplan-
tation. We hypothesized that post-reperfusion administered
ARA290 protects against renal I/R injury. For that purpose,
ARA290 was tested in a porcine renal I/R model.
Materials and methods
Animals
Eight Dutch Landrace pigs (50-70 kg.) were used. They
were housed individually with free access to water. The
pigs were fasted overnight before surgery.
The animal experiments were approved by the animal
ethics committee of the university Groningen (DEC-RuG,
4762, Groningen, the Netherlands) and were performed
according to international and Dutch guidelines of animal
research. The experiment was designed according to the
principle of replacement by alternative methods, reduction
of the number of animals and refinement of experiments
as EU policy as laid out in Towards Responsible Animal
Research (EMBO R 4, 104-107). Based on the assumed ef-
fect size a minimal group size of four was calculated.
ARA290
ARA290 (ARAIM Pharmaceuticals, Ossining, USA) is a
small synthetic peptide consisting of eleven amino acids.
It has been derived from the binding site of EPO to the
protective EPOR2-βcR2 complex and it does not bind to
the classical EPOR2 complex. The plasma half-life is
approximately 2 minutes.
I/R model
In this study we used a unilateral I/R model without
contralateral nephrectomy to reduce animal discomfort
as a refinement. The pigs were randomized either into
the vehicle treated control group or the ARA290 group.
Four animals were included in each group. Saline was
used as vehicle treatment. ARA290 (10 nmol/kg) or
saline was administered intravenously. Animals were
treated at 0, 2, 4 and 6 hours post-reperfusion.
Prior to the procedure ketamine, xylazine and atropine
were administered intramuscularly to reduce anxiety.
General anaesthesia was induced by intravenous admi-
nistration of midazolam and maintained with isoflurane
2,5%. Intubation and surgical conditions were optimized
using pancuronium and analgesia was performed with
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chanically ventilated.
The jugular vein and the carotid artery were cannulated
and surgery was started by a medial laparotomy. The left
renal artery and renal vein were dissected and prior to
clamping heparin (70 IU/kg) was injected intravascularly.
Prior to ischemia a blood sample as well as a needle biopsy
were taken. Baseline renal cortical perfusion was checked
by Laser Doppler (t=-45). Renal ischemia for 45 minutes
was induced by clamping both the renal artery and renal
vein. During ischemia the ureter of the ischemic kidney
was cannulated and subsequently tunnelled to the dorsal
site of the animal. The cannula ended in a small backpack
and it was connected to a swivel system. After 43 minutes
of ischemia a blood sample and biopsy of the ischemic
kidney were taken (t=-2). At t=0 blood flow was restored
by removal of the clamps. At t=15 the last needle biopsy
was taken as well as a blood sample after which the abdo-
men was closed. Animals were allowed to wake up and
housed in adjacent metabolic cages in a temperature con-
trolled environment
During the seven day follow-up, daily blood samples
were taken via the cannulated jugular vein enabling stress
free blood sampling. Urine was collected continuously via
swivel system connected to the ischemic kidney.
After seven days animals were anesthetized and the
kidneys were exposed. Before removal of both the ische-
mic and the contralateral kidneys, they were flushed via
the aorta using Ringer’s Lactate at 4°C. Subsequently all
animals were sacrificed by administration of lethal dose
of pentobarbital.
Samples
Blood and urine samples were stored at -80°C. A cortical
sample of the kidney was snap frozen in liquid N2 and
stored at -80°C for qRT-PCR analyses. For immunohisto-
chemistry and morphology a cortical sample was fixated
in 4% formalin and subsequently embedded in paraffin.
Glomerular filtration rate
Primary endpoint of the study was renal function
defined as glomerular filtration rate (GFR). In our
model plasma creatinine levels cannot be used to moni-







TGF- β GGGAGGGTGTTCATGGTAGGAwill compensate the loss of renal function of the I/R
kidney. To be able to measure renal function of the I/R
kidney, we cannulated the ureter of this kidney. In this
way we were able to monitor urinary output of the I/R
kidney continuously. This technique diminishes animal
discomfort which justifies the more complex determin-
ation of renal function. The GFR of the I/R kidney was
calculated using plasma creatinine levels and urinary
creatinine excretion of the I/R kidney. The GFR was cal-
culated using the following formula: GFR = urinary cre-
atinine level (mM) * urine volume (ml)/plasma creatinine
level (mM) * time (minutes).
Real-time reverse transcription polymerase chain reaction
(qRT-PCR)
RNA was extracted from snap frozen tissue using Trizol
reagent according to the manufacturer’s instructions
(Invitrogen, Breda, the Netherlands). Total RNA was
treated with DNAse I to remove genomic DNA conta-
mination (Invitrogen, Breda, the Netherlands). The in-
tegrity of total RNA was analysed by gel electrophoresis.
cDNA synthesis was performed from 1-μg total RNA
using M-MLV (Moloney murine leukaemia virus) Reverse
Transcriptase and oligo-dT primers (Invitrogen, Breda,
The Netherlands).
Primer sets were designed using Primer Express 2.0 soft-
ware (Applied Biosystems, Foster City, CA). Amplification
and detection were performed with the ABI Prism 7900-
HT Sequence Detection System (Applied Biosystems)
using emission from SYBR green master mix (Applied
Biosystems). The PCR reactions were performed in tripli-
cate. After an initial activation step at 50°C for 2 min and
a hot start at 95°C for 10 min, PCR cycles consisted of 40
cycles at 95°C for 15 sec and 60°C for 60 sec. Dissociation
curve analysis were performed for each reaction to ensure
amplification of specific products.
Gene expression of TNF-α, IL-6, MCP-1, α-SMA, TGF-
β and β-actin (housekeeping gene) were determined.
Primers are shown in Table 1. Gene expression was
normalized with the mean of β-actin mRNA content and
calculated relative to controls or contralateral kidneys.
Results were finally expressed as 2–ΔCT (CT threshold
cycle), which is an index of the relative amount of mRNA







Figure 1 Effect of ARA290 on clinical markers of renal function.
No differences were found in plasma creatinine levels (1A) or urine
flow (1B) between vehicle- or ARA290 treated animals. The GFR of
ARA290 treated animals was significantly increased in the first seven
days post-reperfusion. ARA290 resulted in immediate renal function,
while control kidneys started functioning after 48 hours (1C, p<0.05).
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In paraffin embedded kidney samples were cut into 3-μm-
thick sections. The morphology was evaluated by Periodic
Acid-Schiff (PAS) staining. Immunohistochemical staining
for α-SMA (pre-fibrotic changes) was performed.
Deparaffinised sections were subjected to antigen re-
trieval. The sections for α-SMA staining were incubated
for one night in 0.1M Tris/HCl buffer (pH 9.0).Next, endogenous peroxidase was blocked using 0,3%
H2O2 for 30 minutes. The incubation time of the α-SMA
antibody (1:10000, Clone 1A4, Sigma) was 1 hour. For
the α-SMA staining we used a secondary peroxidase-
conjugated goat-anti-mouse antibody (1:100, DAKO,
Glostrup, Denmark) and a tertiary peroxidase-conjugated
rabbit-anti-goat antibody (1:100, DAKO, Glostrup,
Denmark). The incubation time of the secondary and
tertiary antibodies was 30 minutes. Then the peroxidase
activity was visualized by 3,3-diaminobenzidine tetra-
chloride (DAB) incubation for 10 minutes.
Subsequently, the sections were scanned using APERIO
scanscope (Aperio, Vista, United States). The expression
of the immunohistochemical staining of each section was
quantified using APERIO image scope software.
NOx determination
Total nitrite and nitrate levels (NOx) in blood and urine
were used as a marker of nitric oxide synthase activity.
As nitrite oxidizes rapidly to nitrate, we used the enzyme
nitrate reductase to convert nitrate into nitrite. Next the
nitrite levels were determined using the Griess reaction
[17]. NOx clearance was calculated using the following
formula: NOx clearance = urine flow (ml/min) * urinary
NOx (μmol/ml)/plasma NOx (μmol/ml).
Statistical analyses
All data are presented as mean±standard error of the
mean (SEM). To analyse the data the two-way ANOVA
or the Mann-Whitney U test was used depending on
type of data. p<0.05 was considered significant.
Results
ARA290 improved renal function
Plasma creatinine levels of all animals increased in the
first 24 hours after reperfusion. After the first day,
plasma creatinine levels declined during the remaining 6
days. Plasma creatinine levels and urine flow did not
differ between vehicle- and ARA290 treated animals
(Figure 1A and B). The glomerular filtration rate (GFR)
of the I/R kidney was calculated based on daily plasma
creatinine levels and 24-hours urine via the cannulated
ischemic kidney. The GFR of the I/R kidney was mark-
edly increased by ARA290 treatment post-reperfusion in
the first seven days post-reperfusion (p<0.05, Figure 1C).
No differences were found in haemoglobin, haematocrit,
urea or aspartate transaminase plasma levels. No cardio-
vascular adverse events were observed in vehicle- or
ARA290 treated animals.
The anti-inflammatory effect of ARA290
Two minutes prior to reperfusion, after 43 minutes of is-
chemia, interleukin-6 (IL-6) and monocyte chemotactic
protein-1 (MCP-1) mRNA expression doubled. At this
Figure 2 Effect of ARA290 on acute inflammation. Warm ischemia doubled mRNA expression of IL-6 and MCP-1 at 2 minutes prior to
reperfusion. ARA290 tends to reduce mRNA expression of IL-6 and MCP-1 relative to baseline only 15 minutes after the first administration of
ARA290, indicative of its direct anti-inflammatory effect (p=0.06).
Figure 3 Effect of ARA290 on structural damage. The
morphology of ischemic kidneys at seven days post-reperfusion is
shown by a PAS staining in representative sections of control group
(3A) and ARA290 treated group (3B). ARA290 attenuated
morphological injury at seven days post-reperfusion.
Immunohistochemical α-SMA staining shows expression at seven
days post-reperfusion in the control group (3C) and the ARA290
treated group (3D).
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and there are no differences in mRNA expression of IL-
6 or MCP-1 (Figure 2). ARA290 tended to reduce an
early increase of IL-6 and MCP-1 mRNA expression at 15
minutes post-reperfusion relative to the baseline (p=0.06,
Figure 2). In contrast to IL-6 and MCP-1, ARA290 did not
influence tumour necrosis factor- α (TNF-α) mRNA ex-
pression at 15 minutes post-reperfusion. Seven days post-
reperfusion no differences in inflammation were found.
ARA290 reduced structural damage
In the control group I/R kidneys show morphological
interstitial fibrotic injuries by PAS staining. These processes
are markedly reduced in ARA290 treated animals
(Figure 3A and B). To further investigate these interstitial
processes an immunohistochemical staining for α –smooth
muscle actin (α-SMA) was performed (Figure 3C and D).
Quantification of the intensity showed increased interstitial
α-SMA expression in the ischemic kidneys of the controls
compared to the contralateral kidneys, indicative of fibrotic
changes. ARA290 prevented the interstitial increase of
α-SMA expression (p<0.05, Figure 4). In addition to the
immunohistochemical staining, α-SMA mRNA and trans-
forming growth factor- β (TGF-β) mRNA expression were
measured. ARA290 prevented the increase of TGF-β
mRNA expression in the ischemic kidney at seven days
post-reperfusion relative to the contralateral kidney. Also
an increase in α-SMA mRNA expression tends to be pre-
vented (Figure 5A and B).
The effect of ARA290 on nitric oxide synthase activity
ARA290 did not influence total nitrite and nitrate (NOx)
plasma levels. However, 24 hours post-reperfusion urinaryNOx excretion of ARA290 treated animals was signifi-
cantly increased compared to the controls (p<0.05,
Figure 6A). ARA290 also increased NOx clearance com-
pared to vehicle treatment at 24 hours post-reperfusion
(p<0.05, Figure 6B).
Discussion
The present study shows that ARA290, a synthetic EPO
derivative, administrated post-reperfusion is beneficial in
renal ischemia reperfusion injury. ARA290 increased
GFR in the first seven days post-reperfusion, indicative
of improved renal function. Moreover, ARA290 pre-
vented structural damage evidenced by reduced α-SMA
and TGF-β expression. ARA290 tends to reduce acute
inflammation. Importantly, we did not observe any
Figure 6 Effect of ARA290 on urinary NOx concentration and
NOx clearance. ARA290 tended to result in an immediate increase
in urinary NOx concentration. At 24 hours post-reperfusion urinary
NOx concentration is significantly increased by ARA290 (p<0.05, 6A).
At 24 hours post-reperfusion administered ARA290 increased NOx
clearance (6B, p<0.05).
Figure 4 Effect of ARA290 on interstitial α-SMA expression.
Intensity of the interstitial α-SMA staining has been quantified using
APERIO scanscope. ARA290 prevented an increase of interstitial
α-SMA expression relative to the contralateral kidneys (4, p<0.05).
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ARA290 treated animals. The number of animals was
calculated for the primary endpoint and limits any con-
clusions concerning secondary outcomes. Nevertheless,
the effect of ARA290 on the main outcome parameter,
renal function, is profound.
A number of studies have shown that EPO and EPO
analogues can be renoprotective in renal I/R injury [4-6].
It has already been shown in vitro and in vivo that
ARA290 does not bind the erythropoietic EPOR2 com-
plex [9,15]. This suggests that the main cytoprotective
route of EPO and EPO analogues is mediated by binding
to the EPOR2-βcR2 receptor complex. Unfortunately, the
exact distribution of this receptor complex in renal
tissue is unclear as there is no antibody for the EPOR2-
βcR2 receptor complex available. Cassis et al. observed
tubular staining of both the EPOR and βcR in healthyFigure 5 Effect of ARA290 on mRNA expression of markers of
structural damage. qRT-PCR analyses show TGF-β and α-SMA
mRNA expression at seven days post-reperfusion relative to
contralateral kidney. ARA290 prevented an increase of TGF-β mRNA
expression (p<0.05, 5A). A similar tendency was observed in α-SMA
mRNA expression (5B).kidneys. Ischemia resulted in increased tubular expre-
ssion of the EPOR. Besides also the vessels and glom-
eruli showed faint EPOR and βcR staining after ischemia
[18]. This suggests EPOR and βcR are distributed in
both vascular and tubular tissue after renal ischemia/
reperfusion injury. The proposed cytoprotective pathway
of the EPOR2-βcR2 receptor complex is the Janus
kinase-2 (JAK-2) pathway. In vitro it has been shown
that the JAK-2 pathway is required for protection by
EPO [19]. Phosphorylation of JAK-2 results in potent
anti-inflammatory and anti-apoptotic effects. ARA290
influences downstream pathways of JAK-2, such as acti-
vation of pro-survival pathway Akt and inhibition of
pro-inflammatory pathways p38 mitogen activated pro-
tein kinase, glycogen synthase kinase-3β and nuclear
factor-κβ [20-22]. In this study design it was not possible
to measure activation of these pathways as tissue sam-
ples suitable for western blot analysis were obtained
seven days post-reperfusion.
The anti-inflammatory or anti-apoptotic effects do not
explain the immediate improvement of renal function.
Activation of eNOS is also a downstream result of JAK-2
phosphorylation [7] and most interestingly eNOS is able
to induce a direct increase of GFR [23]. Patel et al.
showed that ARA290 treatment after renal ischemia
increases eNOS phosphorylation in rats. Our study was
focussed on the functional effect of ARA290 and in this
study design we are not able to measure eNOS phos-
phorylation. However, we did observe increased urinary
NOx clearance. This suggests an increased activity of ni-
tric oxide synthase. Unfortunately, we cannot distinguish
between NOx derived from activated eNOS or the inflam-
matory, inducible NOS. Based on the anti-inflammatory
capacities of ARA290 and the increased eNOS phosphor-
ylation shown by Patel et al., the increased NOx clearance
is presumably the result of enhanced eNOS activity.
The cytoprotective pathway of ARA290 needs further
investigation to fully understand this promising way of
tissue protection.
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The immediate stimulative effect of ARA290 treatment
post-reperfusion makes ARA290 a potential drug to
reduce DGF and PNF following renal transplantation. Its
effect on structural damage suggests that also graft sur-
vival could be positively affected by ARA290 treatment
post-transplantation. The advantage of ARA290 when
compared to other cytoprotective treatments is the mo-
ment of administration. The majority of protective agents
or regimen against I/R injury have to be administered
prior to- or during ischemia, while ARA290 can be admi-
nistered post-reperfusion.
This has significant clinical advantages: especially, in
DCD transplantation it is ethically and practically not
possible to treat the donor. Therefore, cytoprotective
treatment of the recipient is necessary to improve short-
and long-term outcome of organs retrieved from these
donors. Since DCD donors are far more available than
DBD donors, improving the quality and function of DCD
donor kidneys is an opportunity to reduce the shortage of
donor organs.
In conclusion, this study shows the renal protective
effect of early administration of ARA290 post-reperfusion.
ARA290 lacks the erythropoietic capacities of EPO and
does not increase the risk of cardiovascular adverse events.
Therefore, ARA290 may translate this promising way of
cytoprotection to the transplantation clinic. Further re-
search should focus on the protective mechanism and the
long-term effect of ARA290 in models of renal transplant-
ation. Based on the results of this study, ARA290 is a
promising drug to prevent I/R injury and to improve renal
function rapidly following renal transplantation.
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